Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17072323 | 0.99 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HRH3HSD11B1 | |
| SCHEMBL4170635 | 0.85 | MEN1 (0.38) | HRH3HSD11B1MEN1KMT2A | |
| SCHEMBL3470172 | 0.85 | HSD11B1 (0.37) | SLC6A2SLC6A4SLC6A3HRH3HSD11B1 | |
| SCHEMBL3470011 | 0.85 | MEN1 (0.37) | HRH3HSD11B1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4185801 | 0.79 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL5090091 | 0.79 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL31284725 | 0.79 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL16213934 | 0.79 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL4194655 | 0.79 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL16214795 | 0.79 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303207-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments | NEUROVANCE, INC. (US) | 2014-10-09 | — | — | US | claimed |
| EP-2167083-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLOÝ3.1.0¨HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV Pharmaceutical, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| WO-2008153937-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV PHARMACEUTICAL, INC. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-20210047268-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMISTTERS | ETHISMOS RESEARCH, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20180215710-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | EUTHYMICS BIOSCIENCE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20170204088-A1 | NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ETHISMOS RESEARCH, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204088-A1 | NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ETHISMOS RESEARCH, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204088-A1 | NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ETHISMOS RESEARCH, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9597315-B2 | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments | EUTHYMICS BIOSCIENCE, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9597315-B2 | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments | EUTHYMICS BIOSCIENCE, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20140303207-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments | NEUROVANCE, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303207-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments | NEUROVANCE, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303207-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments | NEUROVANCE, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140228421-A1 | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters | ETHISMOS RESEARCH, INC. | 2014-08-14 | — | — | US | disclosed |
| EP-2167083-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLOÝ3.1.0¨HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV Pharmaceutical, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090069374-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments | ETHISMOS RESEARCH, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069374-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments | ETHISMOS RESEARCH, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069374-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments | ETHISMOS RESEARCH, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2008153937-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV PHARMACEUTICAL, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047268-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMISTTERS | SLC18A2, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 3/4885 |
| US-20140228421-A1 | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 4/4885 |
| US-20140303207-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments | HTR3C, HTR2C, CNR1 | SLC6A2 385/4885SLC6A4 364/4885SLC6A3 206/4885 |
| US-20170204088-A1 | NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HTR3C, HTR2C, GRIN2C | SLC6A2 407/4885SLC6A4 476/4885SLC6A3 226/4885 |
| US-20180215710-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 4/4885 |
| US-20090069374-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments | HTR3C, HTR2C, GRIN2C | SLC6A2 407/4885SLC6A4 476/4885SLC6A3 226/4885 |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.